Tresiba Self-Injection Technique: How to Inject Insulin Degludec Correctly

How Insulin Degludec Works in the Body

Insulin degludec differs from older basal insulins through its unique multi-hexamer depot mechanism. After subcutaneous injection, degludec molecules self-associate into long chains of di-hexamers in the presence of zinc and phenol from the formulation. These soluble multi-hexamer chains create a slow-release reservoir under the skin, with individual monomers gradually dissociating into the bloodstream over more than 42 hours 1.

This pharmacokinetic profile produces a half-life of approximately 25 hours, roughly twice that of insulin glargine U-100 2. The result is a flat, stable glucose-lowering effect with a within-day variability four times lower than glargine U-100, as measured by euglycemic clamp studies in patients with type 1 diabetes 2. The clinical consequence is direct: a more predictable basal insulin effect and reduced risk of hypoglycemia, particularly overnight.

The DEVOTE trial (N=7,637), a cardiovascular outcomes study published in the New England Journal of Medicine, confirmed that degludec was non-inferior to glargine U-100 on three-point MACE (HR 0.91; 95% CI 0.78-1.06) while producing a 40% reduction in severe nocturnal hypoglycemia (rate ratio 0.47; P<0.001) 3. Because the depot mechanism does not depend on precipitation at the injection site (as glargine does), absorption is less sensitive to injection depth, site vascularity, and local temperature variations.

Preparing the FlexTouch Pen Before Injection

Every injection begins with proper pen preparation. Skipping these steps is the most common cause of inaccurate dosing reported in insulin pen technique surveys 4.

Step-by-step pen preparation:

1. Check the insulin. Remove the pen cap and inspect the solution. Tresiba should be clear and colorless. Do not use the pen if the liquid appears cloudy, contains particles, or has changed color.
2. Attach a new needle. Peel the paper tab from a disposable pen needle and screw it straight onto the pen tip. The FDA-approved prescribing information specifies using a new needle for each injection 5. Reusing needles increases injection pain and raises infection risk.
3. Prime the pen (air shot test). Turn the dose selector to 2 units. Hold the pen with the needle pointing upward, tap the cartridge gently to move any air bubbles to the top, then press the injection button until the dose counter returns to 0 and a drop of insulin appears at the needle tip. If no drop appears, repeat the priming process up to 6 times. A pen that still fails to prime should be discarded.

The American Diabetes Association's consensus report on insulin delivery recommends priming before every injection, noting that failure to prime is associated with dose inaccuracy of up to 30% in some pen systems 4.

Choosing and Rotating Injection Sites

Three anatomical regions are approved for Tresiba injection: the abdomen (at least 2 inches from the navel), the front of the thigh (middle third), and the back of the upper arm (outer area) 5.

Site selection matters less for degludec than for rapid-acting insulins. A pharmacokinetic study comparing abdominal, thigh, and upper arm injections of degludec found no clinically significant differences in total exposure (AUC) or maximum concentration across sites 6. This stands in contrast to regular human insulin, where abdominal injection produces 20-30% faster absorption than thigh injection. The multi-hexamer depot mechanism buffers site-dependent absorption variability.

Rotation within a chosen region remains necessary. Injecting repeatedly into the same spot causes lipohypertrophy (fatty lumps under the skin), which affects 30-50% of insulin-treated patients according to a systematic review of 26 studies 7. Lipohypertrophic tissue absorbs insulin erratically, leading to unexplained glucose swings and increased insulin requirements. A practical approach: imagine a clock face on your abdomen and move one "hour" position with each injection, returning to the starting point only after completing the full circle.

Dr. Laurence Hirsch, Vice President of Medical Affairs at BD (a major pen needle manufacturer), has stated: "The single most impactful change patients can make to improve insulin absorption consistency is to rotate sites systematically and never reuse needles."

Step-by-Step Injection Technique

Correct injection technique determines whether the full prescribed dose reaches the subcutaneous tissue. A 2016 global injection technique survey of 13,289 patients across 42 countries found that 39.1% of insulin users had at least one technique error significant enough to affect glycemic control 4.

The injection sequence:

1. Dial the prescribed dose. Turn the dose selector until the dose counter displays your prescribed number of units. The FlexTouch U-100 pen delivers 1-80 units in 1-unit increments. The U-200 pen delivers 2-160 units in 2-unit increments. The dose window shows units of insulin regardless of concentration, so no conversion math is needed.
2. Pinch or flatten the skin (if needed). For 4 mm needles, most adults can inject into a skin fold or directly into flat skin at a 90-degree angle. For needles 5 mm or longer, pinching a fold of skin between thumb and forefinger reduces the risk of intramuscular injection, particularly in lean individuals 8.
3. Insert the needle. Push the needle straight into the skin at a 90-degree angle. Quick, firm insertion is less painful than slow entry.
4. Press the injection button. Push the button all the way in with your thumb and hold it.
5. Count to 6. Keep the button fully depressed and the needle in the skin for at least 6 seconds after the dose counter returns to 0. The FlexTouch pen's mechanism requires this dwell time to deliver the complete dose. Withdrawing early can cause insulin to leak from the injection site, resulting in a 2-8% dose loss per the manufacturer's data 5.
6. Withdraw and dispose. Pull the needle straight out. Do not rub the injection site. Remove the needle from the pen and dispose of it in a sharps container. Recap the pen.

The 2020 Forum for Injection Technique & Therapy (FITTER) recommendations, endorsed by diabetes education bodies across 54 countries, state: "A 4 mm pen needle is the safest option for all adult patients, including those with obesity, as it reliably reaches subcutaneous tissue while minimizing intramuscular injection risk" 8.

Dose Timing Flexibility: Tresiba's Unique Advantage

One of degludec's defining clinical advantages is dose-timing flexibility. The prescribing information permits once-daily injection at any time of day, with a minimum 8-hour interval between consecutive doses 5. This is a wider window than glargine U-100, which is typically prescribed at the same time each day.

The Flex-T1 and Flex-T2 trials tested intentional dose-timing variation. In Flex-T2 (N=687), patients with type 2 diabetes who rotated injection times to create intervals ranging from 8 to 40 hours between doses achieved the same HbA1c reduction as patients injecting at a fixed time, with no increase in hypoglycemia 9. This flexibility exists because the 25-hour half-life and flat pharmacodynamic profile mean the drug maintains effective circulating levels even when dosing intervals shift by several hours.

For patients with irregular schedules (shift workers, frequent travelers, or anyone who simply forgets their injection occasionally) this pharmacokinetic property translates into fewer missed or doubled doses. Missed doses are the leading cause of basal insulin therapy failure in real-world adherence studies, affecting approximately 25% of insulin-treated patients 10.

Common Injection Errors and How to Fix Them

Technique errors are surprisingly prevalent among experienced insulin users, not just new patients. The ITQ survey found no statistically significant difference in error rates between patients who had been injecting for more than 10 years and those within their first year 4.

Failure to prime. Air trapped in the cartridge displaces insulin volume, meaning the delivered dose may be several units short. Fix: prime 2 units before every injection without exception.

Needle reuse. Used pen needles develop microscopic barbs on the tip that increase pain, can cause bruising, and may introduce bacteria. A single-use needle has a tip diameter of approximately 0.18 mm; after five uses, tip deformation is visible under electron microscopy 4. Fix: use a fresh needle each time. If cost is a barrier, manufacturer patient assistance programs and many insurance formularies cover pen needle supplies.

Injecting into lipohypertrophic tissue. Patients often prefer these sites because the lumps contain fewer nerve endings and injections hurt less. The absorption from lipohypertrophic tissue is both reduced and unpredictable, with studies showing up to a 25% reduction in insulin exposure 7. Fix: healthcare providers should palpate injection sites at every visit. Switching away from affected sites frequently requires a 10-20% dose reduction because normal tissue absorbs the drug more efficiently.

Withdrawing the needle too quickly. A droplet of insulin on the skin surface after removal indicates incomplete delivery. Fix: count a full 6 seconds (some clinicians recommend 10 seconds for doses above 40 units) before withdrawing.

Wrong injection depth. Intramuscular injection accelerates absorption unpredictably and increases pain. Injecting too superficially (intradermal) causes local irritation and erratic absorption. Fix: use a 4 mm needle at 90 degrees for reliable subcutaneous placement across all BMI categories 8.

Storing Tresiba Pens Correctly

Storage conditions directly affect insulin potency. Degraded insulin looks the same as fresh insulin but delivers less glucose-lowering effect.

Unopened Tresiba pens should be stored in a refrigerator at 2-8°C (36-46°F) until the expiration date printed on the carton. Do not freeze. Insulin that has been frozen must be discarded 5.

Once a pen is in use (the cap has been removed and a needle has been attached), it can be stored at room temperature (below 30°C / 86°F) or refrigerated for up to 56 days. This 8-week in-use window is longer than that of most competing basal insulins (glargine U-100 pens expire 28 days after first use). After 56 days, the pen must be discarded even if insulin remains.

During travel, keep pens out of direct sunlight and do not store them in a car glove compartment, where temperatures can exceed 50°C in summer. An insulated insulin travel case with a cool pack (not direct ice contact) is the standard recommendation from the American Diabetes Association 11.

Switching From Other Basal Insulins to Tresiba

Patients transferring from once-daily glargine (U-100 or U-300) or detemir can usually switch to Tresiba on a unit-for-unit basis when coming from glargine U-100, according to the prescribing information 5. Patients switching from glargine U-300 may need a dose increase because U-300 has lower bioavailability than U-100 formulations.

For patients on twice-daily basal insulin (such as detemir given twice daily), the recommended starting dose of Tresiba is 80% of the total daily basal dose, given once. Blood glucose monitoring should be intensified during the first 1-2 weeks after switching because degludec takes 3-4 days to reach steady state due to its long half-life 2. Dose adjustments during this equilibration period should be conservative, with changes no more frequent than every 3-4 days.

The injection technique itself does not change when switching between basal insulins. Patients already comfortable with pen injection can carry over the same site rotation pattern, needle length, and general procedure. The only technique difference specific to Tresiba is the 6-second hold time (some older pen systems required 10 seconds).

When to Contact Your Healthcare Provider

Seek guidance from your prescriber or diabetes educator if you notice unexplained blood glucose variability despite consistent technique, persistent lumps or indentations at injection sites (signs of lipohypertrophy or lipoatrophy), redness or swelling lasting more than 24 hours after injection (rare allergic reaction to insulin or needle), or if you accidentally inject a double dose. For a double dose of Tresiba, monitor blood glucose hourly for 8-12 hours and keep fast-acting carbohydrates accessible. The long half-life means hypoglycemia risk from overdose can persist for up to 48 hours 5.

A 2019 Diabetes Care analysis found that structured injection technique education reduced HbA1c by 0.28% (P=0.003) and cut unexplained hypoglycemia episodes by 34% over 6 months, independent of dose changes 12. Patients on Tresiba who notice persistent fasting glucose above target despite dose titration should request an injection site inspection before assuming the dose is insufficient.